November 22, 2009

• Home
• Conference Coverage
• Event Calendar
• UroToday International Journal
• Advanced Search

browse categories

Home

Prostate Cancer

Bladder Cancer

Renal Cancer

Testicular Cancer

Penis & Urethra Cancer

BPH & Male LUTS

Erectile Dysfunction (ED)

Prostatitis

Male Infertility & Reproduction

Urinary Incontinence (UI)

Overactive Bladder (OAB)

Stress Urinary Incontinence (SUI)

Female Urology

Peyronie's Disease

IC/PBS/BPS/HBS

Stone Disease

Urologic Trauma and Reconstruction

Infections

Renal Transplantation, Vascular Disease

Adrenal and Retroperitoneum

Pediatric Urology

Related Topics

Geriatric Urology

Laparoscopic & Robotic

Androgen Deficiency

Sexually Transmitted Disease

Disease Resources

November 2009 Su Mo Tu We Th Fr Sa 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30

Home Advanced Prostate Cancer Treatment Resource Center

Advanced Prostate Cancer Treatment Center

Bone Health

Clinical Publications

• Effects of denosumab on bone mineral density in men receiving androgen deprivation therapy for prostate cancer - Abstract
  Tuesday, 27 October 2009
• IPF 2009 - How to handle side effects of hormone therapy (HT) in prostate cancer - Session Highlights
  Monday, 26 October 2009
• IPF 2009 - Treatment of metastatic prostate cancer: New strategies - Session Highlights
  Monday, 26 October 2009
• Intravenous zoledronic acid to prevent osteoporosis in a veteran population with multiple risk factors for bone loss on androgen deprivation therapy - Abstract
  Tuesday, 20 October 2009
• Predicting bone scan findings using sPSA in patients newly diagnosed of prostate cancer: Feasibility in Asian population - Abstract
  Tuesday, 06 October 2009
• Agents targeting prostate cancer bone metastasis - Abstract
  Monday, 05 October 2009
• Bone marrow-derived cathepsin K cleaves SPARC in bone metastasis - Abstract
  Monday, 28 September 2009
• Editorial - Predictors of clinical metastasis in prostate cancer patients receiving androgen deprivation therapy: Results from CaPSURE
  Thursday, 17 September 2009
• Adjuvant therapy with oral sodium clodronate in locally advanced and metastatic prostate cancer: long-term overall survival results from the MRC PR04 and PR05 randomised controlled trials - Abstract
  Wednesday, 16 September 2009
• Predictive implications of bone turnover markers after palliative treatment with (186)Re-HEDP in hormone-refractory prostate cancer patients with painful osseous metastases - Abstract
  Thursday, 10 September 2009
• Whole-body magnetic resonance imaging in the detection of skeletal metastases in patients with prostate cancer - Abstract
  Wednesday, 26 August 2009
• Denosumab in men receiving androgen-deprivation therapy for prostate cancer - Abstract
  Friday, 21 August 2009
• Maratona Urológica 2009 - Treatment of locally advanced/metastatic prostate cancer - Session Highlights
  Wednesday, 19 August 2009
• Dasatinib inhibits the growth of prostate cancer in bone and provides additional protection from osteolysis - Abstract
  Tuesday, 18 August 2009
• Treatment of painful bone metastases in hormone-refractory prostate cancer with zoledronic acid and samarium-153-ethylenediaminetetramethylphosphonic acid combined - Abstract
  Thursday, 13 August 2009
• Alendronate decreases the fracture risk in patients with prostate cancer on androgen-deprivation therapy and with severe osteopenia or osteoporosis - Abstract
  Tuesday, 28 July 2009
• Editorial - Denosumab treatment of prostate cancer with bone metastases and increased urine N-telopeptide levels after therapy with intravenous bisphosphonates: results of a randomized phase II trial
  Friday, 24 July 2009
• Denosumab Treatment of Prostate Cancer With Bone Metastases and Increased Urine N-Telopeptide Levels After Therapy With Intravenous Bisphosphonates: Results of a Randomized Phase II Trial - Abstract
  Monday, 20 July 2009
• Single Infusion of Zoledronic Acid to Prevent Androgen Deprivation Therapy-Induced Bone Loss in Men With Hormone-Naive Prostate Carcinoma - Abstract
  Friday, 10 July 2009
• Osteoporosis Prevention in Prostate Cancer Patients Receiving Androgen Ablation Therapy: Placebo-Controlled Double-Blind Study of Estradiol and Risedronate: N01C8 - Abstract
  Tuesday, 07 July 2009
• International Patterns of Practice in Palliative Radiotherapy for Painful Bone Metastases: Evidence-Based Practice? - Abstract
  Monday, 06 July 2009
• Phase I Study of Concurrent Weekly Docetaxel and Repeated Samarium-153 Lexidronam in Patients With Castration-Resistant Metastatic Prostate Cancer - Abstract
  Monday, 22 June 2009
• Slow Zoledronic Acid Releasing Testis Prostheses in the Treatment of Prostate Cancer Patients with Bone Metastases - Abstract
  Tuesday, 16 June 2009
• Artificial Neural Network to Predict Skeletal Metastasis in Patients with Prostate Cancer - Abstract
  Monday, 15 June 2009
• Prevalence of Skeletal Complications and Their Impact on Survival of Hormone Refractory Prostate Cancer Patients in Japan - Abstract
  Tuesday, 09 June 2009
• ASCO 2009 - The Effect of Toremifene Citrate on BMD in Men on ADT: A Phase III Clinical Trial - Session Highlights
  Monday, 01 June 2009
• ASCO 2009 - Denosumab for Prevention of Fractures in Men Receiving Androgen Deprivation Therapy (ADT) for Prostate Cancer - Session Highlights
  Monday, 01 June 2009
• Risedronate Recovers Bone Loss in Patients With Prostate Cancer Undergoing Androgen-Deprivation Therapy - Abstract
  Friday, 29 May 2009
• Bone Morphogenetic Protein-10 Suppresses the Growth and Aggressiveness of Prostate Cancer Cells Through a Smad Independent Pathway - Abstract
  Thursday, 28 May 2009
• Phase II Trial of Consolidation Docetaxel and Samarium-153 in Patients With Bone Metastases From Castration-Resistant Prostate Cancer - Abstract
  Tuesday, 26 May 2009
• Peripheral or Axial Bone Density Measurements to Identify Osteoporosis in Prostate Cancer Patients Undergoing Androgen Deprivation Therapy? - Abstract
  Thursday, 21 May 2009
• Editorial - Long-Term Changes in Bone Mineral Density and Predicted Fracture Risk in Patients Receiving Androgen-Deprivation Therapy for Prostate Cancer, with Stratification of Treatment Based on Presenting Values
  Tuesday, 19 May 2009
• The Use of F-18 Choline PET in the Assessment of Bone Metastases in Prostate Cancer: Correlation with Morphological Changes on CT - Abstract
  Monday, 04 May 2009
• AUA 2009 - Prostate Cancer: Advanced - Zoledronic Acid is Cost Effective for the Prevention of Skeletal-Related Events in Patients with Prostate Cancer and Bone Metastases in France and Germany - Session Highlights
  Tuesday, 28 April 2009
• AUA 2009 - Prostate Cancer: Advanced - Effects of Twice-Yearly Subcutaneous Denosumab on Bone Mineral Density in Men Receiving Androgen Deprivation Therapy for Non-Metastatic Prostate Cancer - Session Highlights
  Sunday, 26 April 2009
• AUA 2009 - Transforming Growth Factor Beta: Cancer, Bone and Beyond - SBUR/SUO Joint Meeting - Session Highlights
  Saturday, 25 April 2009
• (188)Re-HEDP Combined with Capecitabine in Hormone-Refractory Prostate Cancer Patients with Bone Metastases: A Phase I Safety and Toxicity Study - Abstract
  Friday, 24 April 2009
• Beyond the Abstract - Mechanism of Bone Metastasis: The Role of Osteoprotegerin and of the Host-Tissue Microenvironment-Related Survival Factors
  Wednesday, 22 April 2009
• Editorial - Synergy Between Anti-CCL2 and Docetaxel as Determined by DW-MRI in a Metastatic Bone Cancer Model
  Thursday, 16 April 2009
• Editorial - Randomized Phase II Trial of Denosumab in Patients With Bone Metastases From Prostate Cancer, Breast Cancer, or Other Neoplasms After Intravenous Bisphosphonates
  Tuesday, 31 March 2009
• Editorial - Circulating Prostate Tumor Cells Detected by Reverse Transcription-PCR in Men with Localized or Castration-Refractory Prostate Cancer: Concordance with CellSearch Assay and Association with Bone Metastases and with Survival
  Thursday, 26 March 2009
• Randomized Phase II Trial of Denosumab in Patients With Bone Metastases From Prostate Cancer, Breast Cancer, or Other Neoplasms After Intravenous Bisphosphonates
  Wednesday, 18 March 2009
• What is the Real Impact of Bone Pain on Survival in Patients with Metastatic Hormone-Refractory Prostate Cancer Treated with Docetaxel?
  Thursday, 12 March 2009
• Mechanism of Bone Metastasis: The Role of Osteoprotegerin and of the Host-Tissue Microenvironment-Related Survival Factors
  Tuesday, 10 March 2009
• Protease-Activated Receptor-1 is Upregulated in Reactive Stroma of Primary Prostate Cancer and Bone Metastasis
  Thursday, 19 February 2009
• Editorial - Bone Turnover Markers as Predictive Tools for Skeletal Complications in Men with Metastatic Prostate Cancer Treated with Zoledronic Acid
  Wednesday, 11 February 2009
• Src as a Therapeutic Target in Men with Prostate Cancer and Bone Metastases
  Wednesday, 11 February 2009
• BJUI Mini Reviews - Src as a Therapeutic Target in Men with Prostate Cancer and Bone Metastases
  Friday, 06 February 2009
• Bone-Targeted Therapy: Phase II Study of Strontium-89 in Combination With Alternating Weekly Chemohormonal Therapies for Patients With Advanced Androgen-Independent Prostate Cancer
  Wednesday, 31 December 2008
• Safety and Efficacy of the Specific Endothelin-A Receptor Antagonist ZD4054 in Patients with Hormone-Resistant Prostate Cancer and Bone Metastases Who Were Pain Free or Mildly Symptomatic: A Double-Blind, Placebo-Controlled, Randomised
  Wednesday, 17 December 2008
• Phase II Study Shows Hormone Resistant Prostate Cancer Patients with Bone Metastases Could See Improved Survival with ZD4054
  Wednesday, 03 December 2008
• Bone Imaging in Prostate Cancer
  Wednesday, 13 August 2008
• Hollis-Eden Pharmaceuticals Commences Phase I/II Clinical Trial with APOPTONE™ (HE3235) in Late-Stage Prostate Cancer Patients
  Wednesday, 13 August 2008
• Identification of an Androgen Withdrawal Responsive Phenotype in Castrate Resistant Prostate Cancer (CRPC) Patients (pts) Treated with Abiraterone Acetate (AA)
  Wednesday, 13 August 2008
• Clinical Activity of Ketoconazole and Lenalidomide in Castrate Progressive Prostate Carcinoma (CPPCA): Preliminary Results of a Phase II Trial
  Wednesday, 13 August 2008
• Efficacy of Low-Dose Ketoconazole in Hormone Refractory Prostate Cancer Patients (HRPC): A Single Institution Experience
  Wednesday, 13 August 2008
• Effects of Zoledronate (Z) on Bone Mineral Density (BMD) among African Americans (AA) with Advanced Prostate Cancer, without Skeletal Metastases, Receiving Androgen Ablation Therapy
  Wednesday, 13 August 2008
• Cilengitide in Asymptomatic Metastatic Androgen Independent Prostate Cancer (AIPC) Patients (pts): A Randomized Phase II Trial
  Wednesday, 13 August 2008
• Histopathological Assessment of Prostate Cancer Bone Osteoblastic Metastases
  Friday, 25 July 2008
• Amgen Announces Positive Top-Line Results for Denosumab Treatment of Bone Loss in Men With Non-Metastatic Prostate Cancer Undergoing Androgen Deprivation Therapy
  Tuesday, 15 July 2008
• Osteoclast Targeted Therapy for Prostate Cancer: Bisphosphonates and Beyond
  Wednesday, 09 July 2008
• Dutasteride in the Treatment of Hormone Refractory Prostate Cancer
  Wednesday, 11 June 2008
• Pain Predicts Overall Survival in Men with Metastatic Castration-Refractory Prostate Cancer
  Wednesday, 04 June 2008
• AUA 2008 - Effect of the Specific Src Kinase Inhibitor AZD0530 on Osteolytic Lesions in Prostate Cancer
  Tuesday, 20 May 2008
• AUA 2008 - Mitochondrial DNA Mutation Enables Growth of Prostate Cancer in Bone by Activating Specific Signaling Pathways
  Sunday, 18 May 2008
• Correlation Between BMD and Bone Scintigraphy in Patients with Prostate Cancer
  Wednesday, 14 May 2008
• Prediction of Bone Metastases by Combination of Tartrate-Resistant Acid Phosphatase, Alkaline Phosphatase and Prostate Specific Antigen in Patients with Prostate Cancer
  Friday, 09 May 2008
• Management of Metastatic Prostate Cancer: The Crucial Role of Geriatric Assessment
  Wednesday, 09 April 2008
• Simple Stratification of Survival Using Bone Scan and Serum C-Reactive Protein in Prostate Cancer Patients with Metastases
  Wednesday, 09 April 2008
• EAU 2008 - Zoledronic Acid for the Prevention of Bone Metastases in High-Risk Prostate Cancer Patients
  Friday, 04 April 2008
• BJUI Mini Reviews - Treating Asymptomatic Patients with Hormone-Refractory Prostate Cancer: Hormonal Manipulations for the Urologist
  Tuesday, 11 March 2008
• BJUI Mini Reviews - New Blood-Based Biomarkers for the Diagnosis, Staging and Prognosis of Prostate Cancer
  Tuesday, 11 March 2008
• Combination of Bevacizumab and Docetaxel in Docetaxel-Pretreated Hormone-Refractory Prostate Cancer: A Phase 2 Study
  Monday, 03 March 2008
• Ligand-Independent Androgen Receptor Activity is Activation Function-2-Independent and Resistant to Antiandrogens in Androgen Refractory Prostate Cancer Cells
  Monday, 18 February 2008
• ASCO GU 2008 - High-Risk Disease after Radical Retropubic Prostatectomy : The Case for Systemic Treatment
  Saturday, 16 February 2008
• ASCO GU 2008 - Cardiovascular Mortality Following Androgen Deprivation Therapy for Locally Advanced Prostate Cancer: Analysis of ROG 85-31
  Friday, 15 February 2008
• ASCO GU 2008 - Radiation Therapy: How Much Androgen Deprivation Therapy is Enough?
  Friday, 15 February 2008
• ASCO GU 2008 - Androgen Receptor Reactivation after Androgen Deprivation Therapy
  Friday, 15 February 2008
• Short-Term Neoadjuvant Androgen Deprivation Therapy and External-Beam Radiotherapy for Locally Advanced Prostate Cancer: Long-Term Results of RTOG 8610
  Monday, 21 January 2008
• Mechanisms of Androgen Receptor Activation in Advanced Prostate Cancer: Differential Co-Activator Recruitment and Gene Expression
  Wednesday, 16 January 2008
• Effects of Androgen Deprivation on Glycaemic Control and on Cardiovascular Biochemical Risk Factors in Men with Advanced Prostate Cancer with Diabetes
  Monday, 14 January 2008
• SUO 2007 - Prostate Cancer II: "HRQOL and Prostate Cancer Treatment":"Impact of Androgen Deprivation Therapy on the Health of Prostate Cancer"
  Monday, 03 December 2007
• Intraoperative Radiotherapy for Locally Advanced Prostate Cancer: Treatment Technique and Ultrasound-Based Analysis of Dose Distribution
  Monday, 03 December 2007
• Beyond the Abstract - Persistent Hypocalcemia Induced by Zoledronic Acid in a Patient with Androgen-Independent Prostate Cancer and Extensive Bone Metastases
  Friday, 23 November 2007
• Continuing Benefit of Zoledronic Acid in Preventing Skeletal Complications in Patients with Bone Metastases
  Thursday, 22 November 2007
• Combined Androgen Blockade in Advanced Prostate Cancer: Looking Back to Move Forward
  Wednesday, 21 November 2007
• Pathologic Effects of Testosterone Deprivation
  Friday, 09 November 2007
• Intermittent Versus Continuous Androgen Suppression for Prostatic Cancer
  Tuesday, 06 November 2007
• Bone Health in Prostate Cancer Patients Receiving Androgen-Deprivation Therapy: The Role of Bisphosphonates – Abstract
  Friday, 26 October 2007
• Predictors of Skeletal Complications in Men with Hormone-Refractory Metastatic Prostate Cancer - Abstract
  Tuesday, 02 October 2007
• SIU 2007 MP [08.23] - Zoledronic Acid Produces Benefits in Patients with Early Malignant Bone Disease from Hormone-Refractory Prostate Cancer
  Tuesday, 04 September 2007
• SIU 2007 MP [08.12] - One Single Dose of Zoledronic Acid (Zometa) Annually Can Prevent Bone Mineral Density (BMD) in Patients with Prostate Cancer Treated with LHRH: Early Results of a Randomized Trial
  Tuesday, 04 September 2007
• The Effect of Zoledronic Acid on Bone Mineral Density in Patients Undergoing Androgen Deprivation Therapy - Abstract
  Monday, 13 August 2007
• Lifestyle Factors and Duration of Androgen Deprivation Affect Bone Mineral Density of Patients with Prostate Cancer During First Year of Therapy - Abstracts
  Monday, 13 August 2007
• Docetaxel, Vinorelbine, and Zoledronic Acid as First-Line Treatment in Patients with Hormone Refractory Prostate Cancer: A Phase II Study - Abstract
  Friday, 10 August 2007
• Randomized Controlled Trial of Annual Zoledronic Acid to Prevent Gonadotropin-Releasing Hormone Agonist-Induced Bone Loss in Men with Prostate Cancer - Abstract
  Friday, 10 August 2007
• Zoledronic Acid Treatment at Home: Safety Data from an Observational Prospective Trial - Abstract
  Friday, 10 August 2007
• Decreases in Pain at Rest and Movement-Related Pain During Zoledronic Acid Treatment in Patients with Bone Metastases Due to Breast or Prostate Cancer: a Pilot Study - Abstract
  Thursday, 09 August 2007
• Suppression of Bone Density Loss and Bone Turnover in Patients with Hormone-Sensitive Prostate Cancer and Receiving Zoledronic Acid
  Tuesday, 07 August 2007
• Serial Markers of Bone Turnover in Men with Metastatic Prostate Cancer Treated with Zoledronic Acid for Detection of Bone Metastases Progression
  Friday, 04 May 2007
• The Risk of Renal Impairment in Hormone-Refractory Prostate Cancer Patients with Bone Metastases Treated with Zoledronic Acid
  Thursday, 26 April 2007
• Advanced Prostate Cancer - Comparative Reviews of the Major Guidelines
  Thursday, 12 April 2007
• BJU Intl - Bone and Prostate Cancer Cell Interactions in Metastatic Prostate Cancer
  April 2007
• EAU 2007 - Session on Management Options in Metastatic Prostate Cancer and Bone Health
  Friday, 30 March 2007
• EAU 2007 - Step-Up to CAB May Prolong PSA Response in Patients with Metastatic or Locally Advanced Prostate Cancer
  Thursday, 29 March 2007
• EAU 2007 - Hormonal Treatment for Localized and Advanced Prostate Cancer
  Thursday, 29 March 2007
• EAU 2007 - EAU Session on Management Options in Metastatic Prostate Cancer 1
  Wednesday, 21 March 2007
• The Natural History of Noncastrate Metastatic Prostate Cancer after Radical Prostatectomy
  Wednesday, 03 January 2007
• Absolute Prostate-Specific Antigen Value After Androgen Deprivation Is a Strong Independent Predictor of Survival in New Metastatic Prostate Cancer: Data From Southwest Oncology Group Trial 9346 (INT-0162)
  Tuesday, 12 December 2006
• Survey Reveals Physician Misconceptions of Combined Hormonal Therapy for Advanced Prostate Cancer
  Wednesday, 01 November 2006
• When a Patient is Diagnosed with Prostate Cancer, what Determines Whether he will Receive Early Androgen Ablation? Study Shows that his Choice of Urologist may be More Important Than Tumor Characteristics
  Wednesday, 16 August 2006
• Increased Serum Levels Of Bone-specific Alkaline Phosphatase Correlate With Shorter Survival In Men With Hormone Refractory Prostate Cancer
  Wednesday, 05 July 2006
• AUA 2006 - Society of Urologic Oncology Meeting: Hot Topics in GU Cancer Biology And Translation; Bone and the Microenvironment
  May 2006
• AUA 2006 - Society of Urologic Oncology Meeting: Hot Topics in GU Cancer Biology And Translation; Bone and the Microenvironment
  May 2006
• AUA 2006 - ABST [130] Role Calcium Intake on Bone Mineral Density in Prostate Cancer Patients Under Androgen Deprivation Therapy
  May 2006
• AUA 2006 - ABST [410] Bone Mineral Density in Prostate Cancer Patients Undergoing Initial Androgen Deprivation Therapy: Zoledronic Acid vs. Placebo
  May 2006
• AUA 2006 - ABST [1197] Prognostic value of hemoglobin change after initiation of androgen deprivations therapy for newly diagnosed metastatic prostate cancer: a multivariate analysis of SWOG 8894
  May 2006
• ASCO 2006 Prostate Cancer Symposium - A Presentation on the Use of Zoledronic Acid (ZA) Initiated During the First Year of Androgen Deprivation Therapy (ADT) Increases Bone Mineral Density (BMD) and Suppresses Bone Turnover Markers in Prostate Cancer Patients
  June 2006
• ASCO 2006 Prostate Cancer Symposium - An Abstract Presentation on the Efficacy and Safety of Zoledronic Acid in the Treatment of Skeletal Metastases in Patients with Hormone Refractory Prostate Cancer: A Prospective, Multicenter, Open Label Trial
  June 2006
• EAU 2006 - ABST [139] Zoledronic acid as adjunct to androgen deprivation therapy reduces bone loss in men with prostate cancer
  April 2006
• EAU 2006 - ABST [141] Zoledronic acid reduces skeletal morbidity regardless of previous skeletal events in men with prostate cancer and bone metastases
  April 2006
• EAU 2006 - ABST [142] Effects of skeletal morbidities on longitudinal patient-reported outcomes and survival in patients with metastatic prostate cancer
  April 2006
• EAU 2006 - ABST [288] A phase II clinical study of high-dose Calcitriol plus Docetaxel and Zoledronic acid in hormone-refractory prostate cancer (HRPC)
  April 2006
• Combination Of Zoledronic Acid And Docetaxel Inhibits Prostate Cancer Growth In Experimental Bone Study
  Friday, 14 April 2006
• An Argument For The Use Of Zoledronic Acid In Androgen-Sensitive Prostate Cancer
  Monday, 20 March 2006
• Androgen Deprivation Leads To Bone Loss In Men With Prostate Cancer
  Thursday, 22 December 2005
• Disease Extent In Bone And Bone Pain Predict Skeletal-Related Complications In Patients With Metastatic Prostate Cancer
  Tuesday, 08 November 2005
• BJU Intl - Zoledronic Acid Is Effective In Preventing And Delaying Skeletal Events In Patients With Bone Metastases Secondary To Genitourinary Cancers (PDF)
  November 2005
• Randomized, Open Label, Prospective Study Suggests Zoledronic Acid May Prevent the Development of Bone Metastases in Patients with Advanced Cancer
  Monday, 08 August 2005
• ASCO 2005 - #364: Efficacy and safety of zoledronic acid in the treatment of skeletal metastases in patients with hormone refractory prostate cancer: A prospective, multicenter, open-label trial
  May 2005
• ASCO 2005 - #192: Zoledronic acid (ZA) initiated during the first year of androgen deprivation therapy (ADT) increases bone mineral density (BMD) and suppresses bone turnover markers in prostate cancer patients
  May 2005
• Novartis Drug Aids Bones In Paget's Disease-Study
  Thursday, 01 September 2005
• EAU 2005 - ABST[89] PHARMACOGENOMICS OF ZOLEDRONIC ACID: INHIBITORY EFFECTS ON TUMOUR CELL GENE EXPRESSION PROFILES
  March 2005
• EAU 2005 - ABST[567] ZOLEDRONIC ACID PROVIDES LONG-TERM REDUCTION OF BONE PAIN IN PATIENTS WITH BONE METASTASES SECONDARY TO PROSTATE CANCER
  March 2005
• EAU 2005 - ABST[573] METABOLOMICS THERAPY WITH 2-OXO-GLUTARIC ACID SOLUTION (KARAL SOLUTION) IN PATIENTS WITH HORMONE AND CHEMOTHERAPY INSENSITIVE METASTATIC PROSTATE CANCER LEADS TO AN INCREASE OF PSA DOUBLING TIME AND DECREASE OF BLOOD SUPPLY IN TUMOUR LESIONS
  March 2005
• EAU 2005 - ABST[898] Combined Androgen Blockade Six Months a Year in the Management of Advanced Prostate Cancer: A Randomized Study
  March 2005
• EAU 2005 - ABST[993] WEEKLY DOCETAXEL, ZOLEDRONIC ACID, AND ESTRAMUSTINE IN METASTATIC ANDROGEN-INDEPENDENT PROSTATE CANCER (MAIP)
  March 2005
• EAU 2005 - ABST[982] KETOKONAZOL/HYDROCORTISONE VERSUS ESTRAMUSTINPHOSPHATE IN THE MANAGEMENT OF PSA PROGRESSION FOLLOWING PRIMARY ANDROGEN DEPRIVATION FOR METASTATIC PROSTATE CANCER
  March 2005
• Bone Turnover Marker Levels Predict Outcome of Solid Tumor Metastases to Bone
  Wednesday, 19 January 2005
• Pamidronate Disodium Does Not Decrease Pain Morbidity Compared to Placebo in a Randomized Trial of Men with Metastatic Prostate Cancer
  Monday, 09 February 2004
• Single-fraction Radiotherapy Effectively Treats Painful Bone Metastases
  Monday, 20 October 2003
• Maximal Androgen Blockade for the Treatment of Metastatic Prostate Cancer
  5 February 2003
• Zoledronic Acid Reduces Risk of Skeletal Events with Metastatic Prostate Cancer
  Wednesday, 02 October 2002

Reader Comments

Please log-in or register in order to submit comments.

Powered by AkoComment!

User Rating: / 7
PoorBest
You are ... (please select)A Healthcare ProfessionalA Patient